Determining molecular predictors of adverse drug reactions with causality analysis based on structure learning
暂无分享,去创建一个
Jun Hu | Yong Hu | Hua Xu | Mei Liu | Ruichu Cai | Michael E. Matheny | Jingchun Sun | Hua Xu | Jingchun Sun | M. Matheny | Yong Hu | Ruichu Cai | Mei Liu | Jun Hu | Hua Xu | H. Xu | Hua Xu
[1] Bin Chen,et al. Gaining Insight into Off-Target Mediated Effects of Drug Candidates with a Comprehensive Systems Chemical Biology Analysis , 2009, J. Chem. Inf. Model..
[2] Yoshihiro Yamanishi,et al. Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework , 2010, Bioinform..
[3] Trevor Hastie,et al. Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.
[4] Olivier Bodenreider,et al. The Unified Medical Language System (UMLS): integrating biomedical terminology , 2004, Nucleic Acids Res..
[5] David L Veenstra,et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.
[6] J. Johnson,et al. Pharmacogenomics: the inherited basis for interindividual differences in drug response. , 2001, Annual review of genomics and human genetics.
[7] Magnus Ingelman-Sundberg,et al. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. , 2008, The New England journal of medicine.
[8] Ruichu Cai,et al. Causal gene identification using combinatorial V-structure search , 2013, Neural Networks.
[9] Judea Pearl,et al. A Theory of Inferred Causation , 1991, KR.
[10] Z. Birnbaum,et al. One-Sided Confidence Contours for Probability Distribution Functions , 1951 .
[11] M Pirmohamed,et al. Genetic susceptibility to adverse drug reactions. , 2001, Trends in pharmacological sciences.
[12] R. N. Macsween,et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association , 2000, Gut.
[13] A. Chiang,et al. Data‐Driven Methods to Discover Molecular Determinants of Serious Adverse Drug Events , 2009, Clinical pharmacology and therapeutics.
[14] P. Spirtes,et al. Causation, Prediction, and Search, 2nd Edition , 2001 .
[15] Ruichu Cai,et al. BASSUM: A Bayesian semi-supervised method for classification feature selection , 2011, Pattern Recognit..
[16] Chih-Jen Lin,et al. LIBSVM: A library for support vector machines , 2011, TIST.
[17] E. Simpson,et al. Aromatase deficiency confers paradoxical postischemic cardioprotection. , 2011, Endocrinology.
[18] R. Collins,et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.
[19] Yanli Wang,et al. PubChem: Integrated Platform of Small Molecules and Biological Activities , 2008 .
[20] Hua Xu,et al. Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs , 2012, J. Am. Medical Informatics Assoc..
[21] Carol Friedman,et al. Enhancing Adverse Drug Event Detection in Electronic Health Records Using Molecular Structure Similarity: Application to Pancreatitis , 2012, PloS one.
[22] David S. Wishart,et al. DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..
[23] Jonathan M. Teich,et al. Identifying hospital admissions due to adverse drug events using a computer‐based monitor , 2001, AMIA.
[24] Yong Hu,et al. Software project risk analysis using Bayesian networks with causality constraints , 2013, Decis. Support Syst..
[25] Gregory F. Cooper,et al. Causal discovery from medical textual data , 2000, AMIA.
[26] P. Bork,et al. A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.
[27] P. Corey,et al. Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .
[28] E. Brown,et al. The Medical Dictionary for Regulatory Activities (MedDRA) , 1999, Drug safety.
[29] P. Spirtes,et al. Causation, prediction, and search , 1993 .
[30] Evan Bolton,et al. An overview of the PubChem BioAssay resource , 2009, Nucleic Acids Res..
[31] J. Castle,et al. An integrative genomics approach to infer causal associations between gene expression and disease , 2005, Nature Genetics.
[32] Peter Bühlmann,et al. Estimating High-Dimensional Directed Acyclic Graphs with the PC-Algorithm , 2007, J. Mach. Learn. Res..
[33] U. Meyer. Pharmacogenetics and adverse drug reactions , 2000, The Lancet.
[34] C. Grohé,et al. Expression of oestrogen receptor alpha and beta in rat heart: role of local oestrogen synthesis. , 1998, The Journal of endocrinology.
[35] Ann K Daly. Pharmacogenomics of adverse drug reactions , 2013, Genome Medicine.
[36] A. Fliri,et al. Analysis of drug-induced effect patterns to link structure and side effects of medicines , 2005, Nature chemical biology.
[37] P. Clayton,et al. Diagnosis in bile acid-CoA: amino acid N-acyltransferase deficiency. , 2012, World journal of gastroenterology.
[38] Russ Altman,et al. Pharmacogenomics: Challenges and Opportunities , 2006, Annals of Internal Medicine.
[39] Carol Friedman,et al. Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis , 2011, J. Am. Medical Informatics Assoc..
[40] Philip E. Bourne,et al. Drug Discovery Using Chemical Systems Biology: Identification of the Protein-Ligand Binding Network To Explain the Side Effects of CETP Inhibitors , 2009, PLoS Comput. Biol..
[41] David S. Wishart,et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..
[42] M. Rieder,et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. , 2008, Blood.
[43] Ben Y. Reis,et al. Predicting Adverse Drug Events Using Pharmacological Network Models , 2011, Science Translational Medicine.
[44] Barry C. Jones,et al. DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS , 2004, Drug Metabolism and Disposition.
[45] M. Milik,et al. Mapping adverse drug reactions in chemical space. , 2009, Journal of medicinal chemistry.
[46] P. Bork,et al. Network Neighbors of Drug Targets Contribute to Drug Side-Effect Similarity , 2011, PloS one.
[47] M. Schuemie,et al. Combining electronic healthcare databases in Europe to allow for large‐scale drug safety monitoring: the EU‐ADR Project , 2011, Pharmacoepidemiology and drug safety.
[48] A. Butte,et al. Predicting Adverse Drug Reactions Using Publicly Available PubChem BioAssay Data , 2011, Clinical pharmacology and therapeutics.
[49] Hisashi Kashima,et al. Side Effect Prediction Using Cooperative Pathways , 2009, 2009 IEEE International Conference on Bioinformatics and Biomedicine.
[50] Teresa M. Przytycka,et al. Identifying Causal Genes and Dysregulated Pathways in Complex Diseases , 2011, PLoS Comput. Biol..
[51] E. Simpson,et al. Relative expression of aromatase cytochrome P450 in human fetal tissues as determined by competitive polymerase chain reaction amplification. , 1992, The Journal of clinical endocrinology and metabolism.
[52] J. Overhage,et al. Advancing the Science for Active Surveillance: Rationale and Design for the Observational Medical Outcomes Partnership , 2010, Annals of Internal Medicine.
[53] Michael J. Keiser,et al. Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.
[54] 中尾 光輝,et al. KEGG(Kyoto Encyclopedia of Genes and Genomes)〔和文〕 (特集 ゲノム医学の現在と未来--基礎と臨床) -- (データベース) , 2000 .
[55] P. Bork,et al. Drug Target Identification Using Side-Effect Similarity , 2008, Science.
[56] J. Cossman,et al. Drug Development and the FDA's Critical Path Initiative , 2007, Clinical pharmacology and therapeutics.
[57] Yoshihiro Yamanishi,et al. Predicting drug side-effect profiles: a chemical fragment-based approach , 2011, BMC Bioinformatics.
[58] David S. Wishart,et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..
[59] Bin Chen,et al. PubChem as a Source of Polypharmacology , 2009, J. Chem. Inf. Model..
[60] Russell A. Wilke,et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges , 2008, Nature Reviews Drug Discovery.
[61] Kiyoko F. Aoki-Kinoshita,et al. From genomics to chemical genomics: new developments in KEGG , 2005, Nucleic Acids Res..
[62] C Helma,et al. Prediction of Adverse Drug Reactions Using Decision Tree Modeling , 2010, Clinical pharmacology and therapeutics.
[63] Snigdhansu Chatterjee,et al. Causality and pathway search in microarray time series experiment , 2007, Bioinform..
[64] Susumu Goto,et al. KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..
[65] M. F. Fuller,et al. Practical Nonparametric Statistics; Nonparametric Statistical Inference , 1973 .
[66] A. Bender,et al. Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.
[67] Pradip Kumar Saha,et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. , 2002, American journal of respiratory and critical care medicine.